Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pediatrix Medical GroupFRA:PDC +1.80%55 EV-to-EBITDA is 8.68 as of Jul. 23, 2026, which is 26% below its 10-year median of 11.74. GuruFocus rates FRA:PDC with a GF Score™ of 55/100 and a GF Value™ of €11.54. The stock has 8 warning signs investors should review. Among 506 Healthcare Providers & Services companies, Pediatrix Medical Group ranks better than 63.44% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pediatrix Medical Group's enterprise value is €2,124 Mil.
Pediatrix Medical Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €245 Mil. Therefore, Pediatrix Medical Group's EV-to-EBITDA for today is 8.68.
The historical rank and industry rank for Pediatrix Medical Group's EV-to-EBITDA or its related term are showing as below:
FRA:PDC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -117.82 Med: 11.74 Max: 77.81
Current: 8.5
During the past 13 years, the highest EV-to-EBITDA of Pediatrix Medical Group was 77.81. The lowest was -117.82. And the median was 11.74.
FRA:PDC's EV-to-EBITDA is ranked better than 63.44% of 506
companies
in the Healthcare Providers & Services industry
Industry Median: 10.96
vs FRA:PDC: 8.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Pediatrix Medical Group (FRA:PDC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pediatrix Medical Group's PE Ratio (TTM) for today is calculated as:
Pediatrix Medical Group's share price for today is €22.60.
Pediatrix Medical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.768.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PDC vs SEM, AGL, SGRY: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Pediatrix Medical Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pediatrix Medical Group EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pediatrix Medical Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pediatrix Medical Group's EV-to-EBITDA falls into.
Pediatrix Medical Group's current Enterprise Value is €2,124 Mil.
Pediatrix Medical Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €245 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pediatrix Medical Group (FRA:PDC) has a EV-to-EBITDA of 8.68 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pediatrix Medical Group. This is 26% below median its historical median of 11.74. According to the industry distribution chart, Pediatrix Medical Group ranks #185 out of 506 companies in the Healthcare Providers & Services industry, placing it in the top 36.6%.
Is Pediatrix Medical Group's EV-to-EBITDA too high?
Pediatrix Medical Group's current EV-to-EBITDA of 8.68 is 26% below median its 10-year median of 11.74. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.96. Pediatrix Medical Group's value of 8.68 is 20.8% below this industry median. Based on the distribution chart, Pediatrix Medical Group ranks #185 out of 506 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Pediatrix Medical Group has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Pediatrix Medical Group's EV-to-EBITDA compare to SEM and AGL?
According to the Healthcare Providers & Services industry distribution chart, Pediatrix Medical Group ranks #185 out of 506 companies for EV-to-EBITDA. This puts Pediatrix Medical Group in the upper half of its industry. The industry median EV-to-EBITDA is 10.96. Pediatrix Medical Group's value of 8.68 is 20.8% below this benchmark. While the company's 10-year median is 11.74 vs. the industry median of 10.96, Pediatrix Medical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.96, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pediatrix Medical Group's current EV-to-EBITDA of 8.68 is 20.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pediatrix Medical Group. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pediatrix Medical Group's current EV-to-EBITDA is 8.68, which is 26% below median its own 10-year median of 11.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pediatrix Medical Group stock overvalued right now?
Pediatrix Medical Group (FRA:PDC) has a current EV-to-EBITDA of 8.68. The stock's GF Value™ is €11.54, compared to a current price of €22.60 — trading 95.8% above its estimated fair value. The current EV-to-EBITDA is 8.68, which is 26% below median its 10-year median of 11.74 and 20.8% below the Healthcare Providers & Services industry median of 10.96. Pediatrix Medical Group's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Pediatrix Medical Group (FRA:PDC), the current EV-to-EBITDA is 8.68 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pediatrix Medical Group (FRA:PDC) Overvalued in 2026?
Based on GuruFocus' analysis, Pediatrix Medical Group stock appears to be overvalued.
The current stock price of €22.60 is trading 95.8% above its estimated GF Value™ of €11.54.
Key valuation signals for FRA:PDC:
EV-to-EBITDA: 8.68 (26% below median its 10-year median of 11.74)
GF Value™: €11.54 vs. price of €22.60 (95.8% above fair value)
Industry Position: 20.8% below the Healthcare Providers & Services median (#185 of 506)
No single metric tells the full story. See the FRA:PDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
55GF Score
Get the complete analysis for FRA:PDC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PDC has been successfully added to your 
